How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies

Closed for comments This consultation ended on at   Request commenting lead permission

5 Proposed date for review of guidance

5.1 NICE proposes that the guidance on this technology is considered for review by the guidance executive 3 years after publication of the guidance. NICE welcomes comment on this proposed date. The guidance executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

5.2 If the evidence allows, consideration may be given to an early partial review of this guidance for people who have had 2 previous treatments without previous stem cell transplant. This may be combined with the review of the NICE recommendation for pembrolizumab within the Cancer Drugs Fund in NICE's technology appraisal on pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma which would be conducted as a single technology appraisal of both lines of therapy. NICE welcomes comment on this proposal.

Jane Adam
Chair, appraisal committee A
September 2021